MENLO PARK, Calif., January 12, 2026 — Inquis Medical, a commercial-stage medical technology company focused on venous thromboembolic disease (VTE), announced the successful close of a $75 million Series C financing round to support the national commercial expansion of its AVENTUS™ Thrombectomy System and accelerate development of its next-generation pipeline. The strategic investment follows a pivotal year in which the company transitioned from development to commercialization, supported by expanded regulatory clearances and published clinical evidence demonstrating the system’s safety and effectiveness in pulmonary embolism.
Science Significance
From a scientific and engineering perspective, the AVENTUS™ Thrombectomy System represents a next-generation approach to mechanical thrombectomy, addressing longstanding challenges in clot removal for pulmonary embolism and other VTE conditions. The platform integrates directional aspiration with in-line autologous blood reinfusion, enabling efficient thrombus removal while minimizing procedural blood loss. At the core of the system is proprietary tissue-sensing technology that provides real-time intra-procedural feedback, allowing physicians to differentiate between blood, clot, and vessel wall. This combination of precision sensing, atraumatic catheter design, and reinfusion capability reflects meaningful innovation in endovascular device science.
Regulatory Significance
Regulatory progress has been central to Inquis Medical’s momentum. The company achieved expanded regulatory clearance for pulmonary embolism, validating the AVENTUS system’s safety profile, performance characteristics, and manufacturing controls required for commercial deployment. Additionally, the publication of pivotal clinical data in a peer-reviewed cardiovascular journal reinforces regulatory confidence by demonstrating robust thrombus removal with no device-related adverse events in a sizable patient cohort. Together, these milestones underscore the system’s alignment with regulatory expectations for evidence-based medical devices used in high-risk, acute care settings.
Business Significance
Advertisement
The $75 million Series C financing marks a major inflection point in Inquis Medical’s growth trajectory. The capital will be used to scale nationwide sales operations, expand physician training programs, and strengthen post-market clinical evidence generation. Following a $40 million Series B completed in 2024, the new round signals strong investor confidence in the company’s commercial execution, clinical differentiation, and long-term market potential. As the VTE market continues to expand, driven by rising incidence and improved diagnosis, Inquis Medical is positioning itself to redefine the standard of care through technology-enabled intervention.
Patients’ Significance
For patients with pulmonary embolism and other forms of VTE, the expansion of the AVENTUS system has direct clinical implications. Mechanical thrombectomy offers a treatment option that can rapidly reduce clot burden, improve hemodynamics, and potentially shorten recovery time. The system’s ability to minimize blood loss through autologous reinfusion is particularly important for patients at higher risk of complications. By supporting broader access to advanced thrombectomy technology, the financing may translate into improved outcomes, reduced procedural risk, and enhanced quality of care for patients facing life-threatening thromboembolic events.
Policy Significance
At the policy level, the announcement reflects broader trends in venture investment supporting clinically validated medical technologies that address high-burden cardiovascular conditions. As healthcare systems emphasize value-based care, patient safety, and procedural efficiency, technologies that demonstrate both clinical benefit and operational advantages are increasingly prioritized. Continued investment in thrombectomy platforms aligns with policy goals aimed at reducing morbidity, optimizing acute care pathways, and supporting innovation through private capital rather than public expenditure alone.
Inquis Medical’s $75 million Series C financing highlights the growing convergence of clinical evidence, regulatory validation, and venture investment in advancing medical technology. By scaling the commercial adoption of the AVENTUS™ Thrombectomy System and investing in future innovation, the company is strengthening its role in the evolving VTE treatment landscape. As deployment expands nationwide, the combination of scientific innovation, regulatory rigor, and strategic capital positions Inquis Medical to make a lasting impact on interventional care for venous thromboembolic disease.
Source: Inquis Medical press release
